Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Elevated Levels of ST2 and sC5b-9 Potentially Predictive of Thrombotic Microangiopathy
February 23rd 2019Christopher E. Dandoy, MD, MSc, discussed how higher levels of soluble suppression of tumorigenicity-2 and soluble terminal complement complex were associated with high-risk thrombotic microangiopathy, a severe complication related to stem cell transplantation.
Dr. Champlin on the Role of EASIX Following Allogeneic Stem Cell Transplant
February 23rd 2019Richard E. Champlin, MD, a professor of medicine at MD Anderson Cancer Center, discusses the association seen between the Endothelial Activation and Stress Index (EASIX) and fluid overload and survival in patients who underwent an allogenic stem cell transplantation.
Pretransplant MRD Prognostic for Outcomes in Adults With ALL
Adults with acute lymphoblastic leukemia had worse outcomes, including lower survival, after myeloablative allogeneic transplantation if they remained positive for minimal residual disease at the time of transplant.
Bempegaldesleukin/Nivolumab Combo May Address Unmet Need in Metastatic Urothelial Carcinoma
February 18th 2019Arlene O. Siefker-Radtke, MD, discusses the promising preliminary data with bempegaldesleukin plus nivolumab in patients with metastatic urothelial carcinoma and the next steps for this combination.
Pembrolizumab Shows Promising Activity in Non-Clear Cell RCC
Single-agent pembrolizumab (Keytruda) showed encouraging antitumor activity as first-line treatment in patients with non-clear cell renal cell carcinoma, especially in those with papillary or unclassified histology.
PARP Inhibitors Hold Promise in mCRPC and Biallelic DNA Repair Gene Defects
February 18th 2019Evan Y. Yu, MD, highlights 2 key studies with PARP inhibitors in metastatic castration-resistant prostate cancer and discussed challenges that need to be addressed in this space in order to further progress.
Dr. Siefker-Radtke on Bempegaldesleukin Plus Nivolumab in Urothelial Carcinoma
February 17th 2019Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the promise of bempegaldesleukin plus nivolumab in the treatment of patients with metastatic urothelial carcinoma.
Pembrolizumab/Cabozantinib Combo Is Well Tolerated, Shows Activity in Metastatic RCC
The combination of pembrolizumab (Keytruda) and cabozantinib (Cabometyx) has antitumor activity in patients with previously treated metastatic renal cell carcinoma and is tolerated at their separate approved doses for this indication.
Dr. Desai on MRI Imaging for Bone Metastases in CRPC
February 16th 2019Arpita Desai, MD, medical oncologist, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the rationale for testing MRI functional imaging for bone metastases in men with castration-resistant prostate cancer.
Dr. Choueiri Discusses Avelumab/Axitinib Data in RCC
February 16th 2019Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses avelumab/axitinib data in renal cell carcinoma.
Layered Treatment With Radium-223 and Abiraterone May Reduce Skeletal Events in mCRPC
In a real-world setting, patients with metastatic castration-resistant prostate cancer who received radium-223 dichloride with abiraterone acetate in a layered fashion experienced a lower rate of symptomatic skeletal events compared with those who received the treatments concurrently.
Enzalutamide Extends Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer
The addition of enzalutamide (Xtandi) to androgen deprivation therapy significantly prolonged radiographic progression-free survival compared with ADT alone in men with metastatic hormone-sensitive prostate cancer.
Darolutamide Improves Metastasis-Free Survival in Nonmetastatic CRPC
Darolutamide added to androgen deprivation therapy significantly improved metastasis-free survival compared with placebo plus ADT in patients with nonmetastatic castration-resistant prostate cancer enrolled in the phase III ARAMIS trial.
Dr. Balar on Rationale for KEYNOTE-057 in NMIBC
February 15th 2019Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the rationale for the KEYNOTE-057 study in patients with non–muscle invasive bladder cancer.
Dr. Tagawa on Sacituzumab Govitecan in Urothelial Carcinoma
February 15th 2019Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses sacituzumab govitecan in the treatment of patients with urothelial carcinoma.
Nivolumab/Ipilimumab OS Benefit Sustained in Long-Term Follow-Up for Frontline RCC
February 13th 2019Nivolumab combined with low-dose ipilimumab continued to demonstrate strong responses and a survival benefit at 30 months’ follow-up as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma.
Pembrolizumab/Axitinib Combo Improves Survival in Frontline RCC
February 12th 2019The combination of pembrolizumab (Keytruda) and axitinib (Inlyta) was associated with a significantly longer progression-free and overall survival compared with sunitinib (Sutent) in treatment-naïve patients with clear cell metastatic renal cell carcinoma.
Hormonal Agents Induce Improved OS in African Americans With Chemo-Naive mCRPC
February 12th 2019African-American men with metastatic castration-resistant prostate cancer treated with novel hormonal therapies—namely abiraterone acetate or enzalutamide—lived 20% longer than their Caucasian counterparts.
